INT20332

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.69
First Reported 1990
Last Reported 2010
Negated 1
Speculated 2
Reported most in Abstract
Documents 4
Total Number 5
Disease Relevance 0.68
Pain Relevance 2.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP1A2) oxidoreductase activity (CYP1A2) endoplasmic reticulum (CYP1A2)
enzyme binding (CYP1A2)
Anatomy Link Frequency
plasma 4
CYP1A2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Duloxetine 84 100.00 Very High Very High Very High
Paracetamol 15 100.00 Very High Very High Very High
Leflunomide 1 96.40 Very High Very High Very High
lidocaine 1 94.80 High High
Endep 1 91.44 High High
Nortriptyline 1 90.84 High High
tricyclic antidepressant 7 90.08 High High
Analgesic 4 81.32 Quite High
depression 18 79.80 Quite High
antidepressant 4 69.20 Quite High
Disease Link Frequency Relevance Heat
Hepatotoxicity 3 98.92 Very High Very High Very High
Sudden Death 1 95.04 Very High Very High Very High
Toxicity 2 83.92 Quite High
Suicidal Behaviour 1 81.24 Quite High
Depression 34 79.80 Quite High
Liver Disease 1 58.64 Quite High
Sleep Disorders 3 56.12 Quite High
Fibromyalgia 147 55.00 Quite High
Nicotine Addiction 2 48.80 Quite Low
Hypertension 2 45.96 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The results of this study show that, despite induction of CYP1A2 activity in slow metabolizers (a 75% increase in plasma clearance of caffeine), the formation of NAPQI from acetaminophen was not increased after 7 days of omeprazole administration (40 mg/day).
Neg (not) Positive_regulation (increased) of Positive_regulation (induction) of CYP1A2 in plasma associated with paracetamol
1) Confidence 0.69 Published 1997 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 9246016 Disease Relevance 0.08 Pain Relevance 0.69
CYP1A2 is one of the major enzymes that bioactivate a number of procarcinogens and thus induction of CYP1A2 may increase the carcinogenicity of these compounds.
Spec (may) Positive_regulation (increase) of Positive_regulation (induction) of CYP1A2
2) Confidence 0.50 Published 2009 Journal Curr. Drug Metab. Section Abstract Doc Link 19702529 Disease Relevance 0 Pain Relevance 0.14
This suggests that induction of CYP1A2 activity by omeprazole is unlikely to increase the risk of acetaminophen hepatotoxicity.
Positive_regulation (increase) of Positive_regulation (induction) of CYP1A2 associated with paracetamol and hepatotoxicity
3) Confidence 0.50 Published 1997 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 9246016 Disease Relevance 0.17 Pain Relevance 0.65
Of clinical relevance, duloxetine does not inhibit or induce the CYP3A4 system, but administration of CYP1A2 inhibitors may result in elevated duloxetine concentrations.42 The CYP1A2 inhibitor thioridazine should not be coadministered with duloxetine due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine.39 Adverse effects on the fetus have been found in animal reproductive studies, rendering duloxetine a Category C agent for women who are pregnant.42
Spec (may) Positive_regulation (result) of Positive_regulation (elevated) of CYP1A2 in plasma associated with duloxetine and sudden death
4) Confidence 0.32 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004640 Disease Relevance 0.43 Pain Relevance 0.69
Omeprazole produced a time- and concentration-dependent increase in (a) cytochrome P450IA2 accumulation determined by western blot in microsomes from omeprazole-treated cells, while the level of other cytochrome P450 forms including P450IID6, IIE1, and IIIA was not increased in the same culture; (b) several monoxygenase activities, including phenacetin deethylase and acetanilide hydroxylase (cytochrome P450IA2) and ethoxyresorufin deethylase and benzpyrene hydroxylase (cytochrome P450IA1); (c) cytochrome P450IA2 de novo synthesis, determined by immunoprecipitation of cell lysate from [3H]Leu-labeled cells; (d) cytochromes P450IA1 and IA2 mRNAs, determined by northern blot analysis.
Positive_regulation (increase) of Positive_regulation (accumulation) of cytochrome P450IA2
5) Confidence 0.09 Published 1990 Journal Gastroenterology Section Abstract Doc Link 2136526 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox